Both compounds have demonstrated favorable safety profiles in preclinical and early clinical research, but combination use has not undergone Phase III human trials
?
Disclosures: Sheila Noon: Nothing to Disclose, Nhat Thai: Nothing to Disclose, Kimberly Newton: Nothing to Disclose, Nidhi Goyal: Nothing to Disclose, Benjamin Maxwell: Nothing to Disclose, Elizabeth Yu: Nothing to Disclose, Warren Shapiro: Nothing to Disclose, Jeffrey Schwimmer: Intercept: Grant/Research Support, Seraphina: Grant/Research Support, Merck: Consultant 1124 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND ASSOCIATED RISK FACTORS IN A COMMUNITY-BASED SAMPLE OF AMERICAN INDIANS David Garcia Edgar Villavicencio 1 Caitlin Baird 1 Xiaoxiao Sun 1 Timian Godfrey 1 Kimberly Shea 1 Adriana Maldonado 1 Denver Seaton 2 Priscilla Sanderson 2 , 1 University of Arizona, 2 Northern Arizona University Background: American Indian (AI) communities experience higher rates of liver cancer incidence and mortality than the general United States population
Comment: Some commenters agreed with our proposal to recognize the signed and dated order for only the initial certification and that the existing signature requirements should be kept for certifications when the patient does not have an order or referral and for all recertifications irrespective of a whether the patient has a referral
Take a photo of the recycling information Transportation Origins of ingredients Missing origins of ingredients information The origins of the ingredients of this product are not indicated
B.VenkateshappaC.HarishG.MahadevanA.MuthaneU
